|Mr. Hedi Ben Brahim||Chairman & CEO||N/A||N/A||1982|
|Mr. Jean-Philippe Del||VP & CFO||N/A||N/A||1981|
|Dr. Ãric QuÃ©mÃ©neur||Exec. VP & Chief Scientific Officer||N/A||N/A||1965|
|Ms. Elisabetta Castelli||Director of Investor Relations||N/A||N/A||N/A|
|Mr. John Felitti||VP, Gen. Counsel & Corp. Sec.||N/A||N/A||1970|
|Lucie Larguier||Director of Corp. Communications & IR||N/A||N/A||N/A|
|Mr. Thibaut du Fayet||VP of Corp. Devel.||N/A||N/A||1968|
|Ms. Gaelle Stadtler||VP & Director of HR||N/A||N/A||N/A|
|Mr. Philippe Slos||Head of Preclinical Regulatory Laboratory||N/A||N/A||N/A|
|Dr. Maud Brandely-Talbot||VP of Medical Affairs & Chief Medical Officer||N/A||N/A||1955|
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma (stomach, pancreas, and colon); and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. It also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. Transgene SA has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Transgene SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.